New drug combo shows promise in stomach cancer battle
NCT ID NCT06206733
First seen Jan 28, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This study tests whether adding the drug ASKB589 to standard chemotherapy and immunotherapy can help people with advanced stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 780 adults whose tumors have a specific marker (CLDN18.2) will receive either the new combination or a placebo plus standard treatment. The goal is to see if the new combo delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing cancer hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.